NICE Rejects Donanemab for NHS Use Due to Cost Concerns

By João L. Carapinha

October 24, 2024

The article from the National Institute for Health and Care Excellence (NICE) on the new Alzheimer’s treatment donanemab highlights several key points regarding the decision not to recommend this drug for use in the NHS. Essentially, donanemab has faced rejection due to concerns over its cost-effectiveness and the limited benefits it provides.

Reason for the Donanemab NHS rejection

NICE has determined that donanemab “does not currently demonstrate value for the NHS.” The NHS based this decision primarily on the drug’s cost-effectiveness; they saw its benefits to patients as too minimal to warrant the significant additional costs. The cost-effectiveness estimate for donanemab is five to six times above the threshold that NICE typically considers acceptable for NHS resources.

Clinical Benefits

While donanemab, manufactured by Eli Lilly, has shown potential to slow cognitive decline in Alzheimer’s patients, the observed benefits are relatively small. Clinical trials indicate that donanemab could result in a delay of cognitive decline by four to seven months. However, NICE’s independent committee concluded that this improvement is not adequate to justify the high costs associated with the treatment.

Regulatory Approval

Despite NICE’s decision, donanemab has received approval from the UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), for use within the UK. This approval is significant as it highlights the drug’s safety and efficacy, but it does not change NICE’s assessment regarding its cost-effectiveness for NHS use.

Impact on Patients and Carers

The rejection of donanemab for NHS use is a considerable setback for patients with early-stage Alzheimer’s and their carers. Advocates argue that drugs like donanemab, along with another rejected treatment called lecanemab, represent the first chance to effectively slow the decline in memory and cognitive abilities associated with Alzheimer’s, rather than merely addressing symptoms. Consequently, the decision may restrict access to these therapies to individuals who can afford private treatment.

Future Implications

This decision raises alarms that the UK could become a less appealing market for launching new dementia treatments due to strict cost-effectiveness standards. Organizations such as Alzheimer’s Research UK and various charities have urged the Health Secretary to take action and initiate discussions among NICE, NHS England, and the pharmaceutical industry. Policymakers aim to ensure that patients with dementia can access new treatments and receive proper attention in the healthcare system.

Ongoing Research and Development

NICE acknowledges that this is an emerging area of medicine and that further treatments are currently being researched. The agency emphasizes that more comprehensive evidence is needed on the clinical and cost-effectiveness of donanemab, suggesting that future reassessments could occur if additional data become available.

Reference url

Recent Posts

modifiable risk factors
        

Targeting Shared Risk Pathways to Prevent Stroke, Dementia, and Depression

🧠 What if addressing just a few key lifestyle factors could significantly reduce the risk of stroke, dementia, and depression in older adults?

A recent systematic review has identified 17 **modifiable risk factors**, revealing the interconnected nature of these age-related brain diseases and offering crucial insights for preventive strategies. By focusing on aspects such as blood pressure management, nutrition, and physical activity, we can enhance quality of life for our aging population.

Dive into the article to explore how these findings could shape future healthcare models.

#SyenzaNews #HealthEconomics #HealthcareInnovation #DigitalTransformation

drug price regulation
      

Navigating Drug Price Regulation: Evaluating the Executive Order’s Potential Impacts and Challenges

💊 Curious about the future of drug pricing in the U.S.?

The recent executive order aims to tackle escalating prescription drug costs through measures like international reference pricing and enhanced transparency. However, the implications of these policies could be more complex than anticipated, with potential risks to market access and innovation.

Dive into the article for a detailed analysis of how these regulations could shape the pharmaceutical landscape and what it means for healthcare access in the U.S.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AI Patient Education
       

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

🤔 Are AI solutions ready to revolutionize pediatric patient education?

A recent study compared ChatGPT and Gemini in generating educational materials for common pediatric conditions, revealing intriguing insights into content depth, readability, and reliability. While both tools have their merits, there’s significant room for improvement in making AI-generated content accessible and effective for all families.

Curious to learn more about the implications for health literacy and the future of AI in healthcare? Click to read the full article!

#SyenzaNews #AIinHealthcare #HealthTech #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.